This document discusses drug induced pulmonary diseases. It defines drug induced pulmonary disease as any lung disease caused by a drug or medication. It then lists and describes 10 types of drug induced pulmonary diseases: 1) bronchospasm, wheezing and cough, 2) pulmonary edema, 3) pulmonary hypertension, 4) interstitial lung disease including interstitial pneumonia/infiltrates and pulmonary fibrosis, 5) pulmonary eosinophilia, 6) pleural inflammation, 7) diffuse alveolar hemorrhage/vasculitis, 8) diffuse alveolar damage, 9) drug hypersensitivity syndrome, and 10) amiodarone induced pulmonary toxicity. For each type of disease, it provides details on symptoms,
Drug induced pulmonary diseases can affect the lungs in several ways such as causing bronchospasm, pulmonary edema, pulmonary hypertension, and various types of interstitial lung disease. Common culprit drugs include antibiotics, chemotherapy agents, cardiovascular drugs, NSAIDs, and illicit drugs. Management involves withdrawal of the causative agent, supplemental oxygen, diuretics, corticosteroids, and occasionally immunosuppressants depending on the type and severity of lung disease. Amiodarone is a known cause of delayed pulmonary toxicity that often requires long term corticosteroid treatment.
This document discusses drug-induced pulmonary diseases. It defines drug-induced pulmonary disease as any lung disease caused by a medication. Some common types of drug-induced pulmonary diseases include bronchospasm, pulmonary edema, pulmonary hypertension, interstitial lung disease, pulmonary eosinophilia, pleural inflammation, diffuse alveolar hemorrhage, diffuse alveolar damage, and drug hypersensitivity syndrome. Specific drugs that can cause each type of lung disease are provided. The document also discusses definitions, symptoms, mechanisms, and management approaches for each type of drug-induced pulmonary disease.
This document discusses drug-induced pulmonary diseases. It outlines several mechanisms by which drugs can cause lung injury, including direct cytotoxic effects, oxidative injury, and immune-mediated reactions. It describes different types of drug-induced lung diseases such as interstitial lung disease, pulmonary edema, bronchospasm, and pulmonary hypertension. Specific drugs that can induce these diseases and their mechanisms are discussed. Diagnosis and treatment approaches for drug-induced pulmonary conditions are also summarized.
Drugs can induce a variety of pulmonary diseases through different mechanisms such as hypersensitivity reactions, direct toxicity, and indirect effects. Common presentations include cough, dyspnea, and abnormal chest imaging. Treatment involves identifying the culprit drug, discontinuing its use, and potentially administering corticosteroids. Early diagnosis is important to prevent long term complications like pulmonary fibrosis.
The document discusses the lower respiratory tract and diseases that affect it such as COPD and restrictive pulmonary diseases. COPD includes chronic bronchitis, bronchiectasis, emphysema, and asthma and results in irreversible lung damage. Restrictive pulmonary diseases decrease total lung capacity through fluid, fibrosis, or tumors. The document also examines the symptoms, causes, and treatments of various lower respiratory diseases including bronchiectasis, emphysema, asthma, and pneumonia. It provides details on drugs used to treat COPD such as sympathomimetics, leukotriene antagonists, cromolyn, and glucocorticoids.
This document discusses eosinophilic pneumonias, which are characterized by infiltration of the lungs with eosinophils. It begins by providing a brief history and classification, dividing causes into those of known cause (such as parasites, drugs, tropical pulmonary eosinophilia) and unknown cause (idiopathic acute eosinophilic pneumonia, chronic eosinophilic pneumonia, Churg-Strauss syndrome, idiopathic hypereosinophilic syndrome). It then discusses several types of eosinophilic pneumonia in more detail, including their presentations, investigations, treatments, and key distinguishing features.
This document summarizes community acquired pneumonia, its types , causes, organisms, CRUB-65 score, difference with atypical pneumonia, investigations, treatment and prevention.
This document discusses drug induced pulmonary diseases. It defines drug induced pulmonary disease as any lung disease caused by a drug or medication. It then lists and describes 10 types of drug induced pulmonary diseases: 1) bronchospasm, wheezing and cough, 2) pulmonary edema, 3) pulmonary hypertension, 4) interstitial lung disease including interstitial pneumonia/infiltrates and pulmonary fibrosis, 5) pulmonary eosinophilia, 6) pleural inflammation, 7) diffuse alveolar hemorrhage/vasculitis, 8) diffuse alveolar damage, 9) drug hypersensitivity syndrome, and 10) amiodarone induced pulmonary toxicity. For each type of disease, it provides details on symptoms,
Drug induced pulmonary diseases can affect the lungs in several ways such as causing bronchospasm, pulmonary edema, pulmonary hypertension, and various types of interstitial lung disease. Common culprit drugs include antibiotics, chemotherapy agents, cardiovascular drugs, NSAIDs, and illicit drugs. Management involves withdrawal of the causative agent, supplemental oxygen, diuretics, corticosteroids, and occasionally immunosuppressants depending on the type and severity of lung disease. Amiodarone is a known cause of delayed pulmonary toxicity that often requires long term corticosteroid treatment.
This document discusses drug-induced pulmonary diseases. It defines drug-induced pulmonary disease as any lung disease caused by a medication. Some common types of drug-induced pulmonary diseases include bronchospasm, pulmonary edema, pulmonary hypertension, interstitial lung disease, pulmonary eosinophilia, pleural inflammation, diffuse alveolar hemorrhage, diffuse alveolar damage, and drug hypersensitivity syndrome. Specific drugs that can cause each type of lung disease are provided. The document also discusses definitions, symptoms, mechanisms, and management approaches for each type of drug-induced pulmonary disease.
This document discusses drug-induced pulmonary diseases. It outlines several mechanisms by which drugs can cause lung injury, including direct cytotoxic effects, oxidative injury, and immune-mediated reactions. It describes different types of drug-induced lung diseases such as interstitial lung disease, pulmonary edema, bronchospasm, and pulmonary hypertension. Specific drugs that can induce these diseases and their mechanisms are discussed. Diagnosis and treatment approaches for drug-induced pulmonary conditions are also summarized.
Drugs can induce a variety of pulmonary diseases through different mechanisms such as hypersensitivity reactions, direct toxicity, and indirect effects. Common presentations include cough, dyspnea, and abnormal chest imaging. Treatment involves identifying the culprit drug, discontinuing its use, and potentially administering corticosteroids. Early diagnosis is important to prevent long term complications like pulmonary fibrosis.
The document discusses the lower respiratory tract and diseases that affect it such as COPD and restrictive pulmonary diseases. COPD includes chronic bronchitis, bronchiectasis, emphysema, and asthma and results in irreversible lung damage. Restrictive pulmonary diseases decrease total lung capacity through fluid, fibrosis, or tumors. The document also examines the symptoms, causes, and treatments of various lower respiratory diseases including bronchiectasis, emphysema, asthma, and pneumonia. It provides details on drugs used to treat COPD such as sympathomimetics, leukotriene antagonists, cromolyn, and glucocorticoids.
This document discusses eosinophilic pneumonias, which are characterized by infiltration of the lungs with eosinophils. It begins by providing a brief history and classification, dividing causes into those of known cause (such as parasites, drugs, tropical pulmonary eosinophilia) and unknown cause (idiopathic acute eosinophilic pneumonia, chronic eosinophilic pneumonia, Churg-Strauss syndrome, idiopathic hypereosinophilic syndrome). It then discusses several types of eosinophilic pneumonia in more detail, including their presentations, investigations, treatments, and key distinguishing features.
This document summarizes community acquired pneumonia, its types , causes, organisms, CRUB-65 score, difference with atypical pneumonia, investigations, treatment and prevention.
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a preventable and treatable disease characterized by airflow limitation caused by cigarette smoking and exposure to other noxious particles. The document outlines the risk factors, pathogenesis, pathophysiology, symptoms, diagnosis, classification, and management of COPD. Spirometry is a key test for COPD diagnosis and assessment. The goals of treatment are to prevent progression, relieve symptoms, improve exercise tolerance, and prevent exacerbations.
Pneumonia is an infection that causes inflammation in the lungs. There are two main types: lobar pneumonia, which affects one lung lobe, and bronchopneumonia, which causes patches throughout both lungs. Pneumonia is usually caused by bacteria or viruses and risks factors include age, smoking, and pre-existing medical conditions. Symptoms may include fever, cough, and difficulty breathing. Diagnosis involves chest x-rays and cultures. Treatment focuses on antibiotics and symptom relief. Complications can include lung abscesses or fluid in the chest cavity.
1. Pneumonia is an inflammation of the lung parenchyma that presents with recent radiological shadowing. It can be misdiagnosed, mistreated, and under estimated.
2. Pneumonia is classified by aetiology (community acquired, hospital acquired, aspiration) and anatomy (lobar, bronchopneumonia).
3. Risk factors include age, comorbidities, respiratory conditions, lifestyle factors, and immunosuppressant therapy.
The document discusses lung abscess and bronchiectasis. It defines lung abscess as a suppurative lesion caused by infected lung tissue necrosis that forms cavities containing pus or fluid. Bronchiectasis is an abnormal, permanent dilation of the bronchi often caused by infection. The document outlines the epidemiology, pathogenesis, clinical features, investigations, management, and prevention of lung abscess and bronchiectasis. It describes the most common causes and pathogens, as well as signs and symptoms, management with antibiotics and drainage, and importance of preventing aspiration to control the conditions.
Chronic Obstructive Pulmonary Disease (COPD) is an irreversible lung disease characterized by limited airflow and an abnormal inflammatory response in the lungs caused by long-term exposure to harmful particles like cigarette smoke. The main symptoms are breathlessness, cough, and wheezing. Diagnosis is based on a history of symptoms and cigarette smoking, and confirmed with lung function tests showing reduced airflow. Treatment focuses on smoking cessation and drug therapy with bronchodilators and corticosteroids to manage symptoms and reduce exacerbations.
Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases including chronic bronchitis and emphysema that are characterized by persistent airflow limitation. The main causes of COPD are tobacco smoking, exposure to secondhand smoke, and air pollution. Symptoms include cough, sputum production, and shortness of breath. Diagnosis involves assessing symptoms, lung function tests, and chest imaging. Treatment focuses on smoking cessation, medications to relieve symptoms and prevent exacerbations, pulmonary rehabilitation, and managing complications.
This document summarizes several respiratory system diseases including chronic obstructive pulmonary disease (COPD) and chronic restrictive pulmonary disease. It describes the four entities that comprise COPD - bronchial asthma, chronic bronchitis, emphysema, and bronchiectasis. For each condition, it outlines characteristics, pathologic findings, and types. It also discusses several occupational lung diseases that fall under chronic restrictive pulmonary disease, including coal workers' pneumoconiosis, silicosis, and asbestosis.
Pneumonia is an inflammation of the lung parenchyma caused by various microorganisms, including bacteria, mycobacteria, fungi, and viruses.
Pneumonitis is a more general term that describes the inflammatory process in the lung tissue that may predispose and Pneumonia is an inflammation of the lung parenchyma that is caused by a microbial agent.
place the patient at risk for microbial invasion.
Pneumonia is classified into four: community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), pneumonia in the immunocompromised host, and aspiration pneumonia.
This document discusses chronic kidney disease and its management. It defines chronic kidney disease as kidney damage and decreased kidney function for over 3 months. It then discusses the pathophysiology of chronic renal failure, noting the loss of nephrons and failure of kidney roles in fluid balance, waste excretion, and hormone regulation. Common causes of chronic kidney disease are listed, and the progression from initial insult to end stage renal disease is described. Diagnosis involves history, exam, and blood and urine tests to assess kidney function and check for underlying etiologies. Treatment focuses on slowing progression, managing complications, and preparing for renal replacement therapies like dialysis and transplantation.
DENTAL MANAGEMENT OF PATIENTS WITH REPIRATORY DISEASES 2809-1.pptxSamuelAgboola11
This document discusses the relationship between the respiratory and oral systems. It begins by describing the structures and functions of the respiratory system, including the conducting airways, lungs, muscles of respiration, and control centers in the central nervous system. It then discusses several respiratory diseases like viral upper respiratory infections, asthma, pneumonia, and tuberculosis. For each disease, it covers signs and symptoms, pathogenesis, and dental management considerations. The document emphasizes the importance of oral health in preventing respiratory infections and managing patients with respiratory diseases.
The document discusses various lower respiratory disorders including:
1. Atelectasis, which is the collapse or closure of the lung resulting in reduced gas exchange. Pneumonia, an inflammation of the lung parenchyma caused by a microbial agent, is discussed along with types such as bacterial, viral, fungal and aspiration pneumonia.
2. Pulmonary tuberculosis, an infectious lung disease caused by the bacterium Mycobacterium tuberculosis, is usually spread through the air. Lung abscess, defined as necrosis of lung tissue and cavity formation caused by microbial infection, is also covered.
3. Other conditions mentioned include pleural conditions, pulmonary edema, acute respiratory failure, pulmonary embolism
The document summarizes key aspects of respiratory pathology. It discusses the anatomy and function of the lungs, as well as various lung diseases including congenital anomalies, atelectasis, pulmonary edema, acute lung injury, obstructive and restrictive lung diseases, infectious diseases like pneumonia and tuberculosis, and cancers. Diseases are described in terms of their definition, causes, pathogenesis, clinical presentation, complications and morphological features.
This document provides an overview of pulmonary edema through defining it, discussing anatomy and physiology, epidemiology, classification, pathogenesis, staging, causes, clinical manifestations, diagnosis, medical management, nursing diagnosis, interventions, complications, and expected outcomes. It summarizes the key points of pulmonary edema for medical professionals.
This document discusses respiratory failure, including its definition, types, causes, clinical manifestations, diagnostic evaluations, management, and complications. Respiratory failure is when the respiratory system fails to adequately oxygenate the blood or eliminate carbon dioxide. It can be classified as hypoxemic or hypercapnic. Acute respiratory failure develops rapidly over hours while chronic develops over days. Management involves treating the underlying cause, providing oxygen supplementation, monitoring vital signs, and supporting respiratory function. Complications can affect the lungs, heart, gastrointestinal system, and risk of infection.
it involves the general principles of poisoning treatment and various basic principles of management of poisoning IT IS USEFULL FOR THE IV.PHARM D STUDENTS AND MEDICAL STUDENTS
Respiratory dis. presentation1 for gen path copy (2)Art Arts
1) Respiratory diseases are mainly caused by inhalation of infectious agents, allergens, irritants, and carcinogens. The lungs are open to the environment and lack regenerative abilities.
2) Chronic obstructive pulmonary diseases (COPD) include chronic bronchitis, emphysema, bronchiectasis, and asthma. Tobacco smoke is a major cause and leads to airway obstruction.
3) Pneumonia can result from impaired pulmonary defenses and host resistance. Bacterial and viral pathogens are common causes and treatment involves antibiotics and supportive care.
The document provides information on pulmonary emergencies including pneumonia, asthma, and chronic obstructive pulmonary disease (COPD). It discusses the common causes, clinical features, diagnostic tests, treatment, and management of each condition. For pneumonia, it outlines the typical bacterial and atypical agents that cause pneumonia in different age groups. It also lists antibiotics commonly used to treat pneumonia. For asthma, it describes the pathophysiology and emphasizes the importance of optimizing lung function and oxygenation. For COPD, it defines the components of the disease and notes the role of medications like bronchodilators, corticosteroids, and antibiotics in management.
Etiopathogenesis and pharmacotherapy of DIPDs
a. the pathophysiology of selected disease states and the rationale for drug therapy;
b. the therapeutic approach to management of these diseases;
c. the controversies in drug therapy;
d. the importance of preparation of individualised therapeutic plans based on diagnosis;
e. needs to identify the patient-specific parameters relevant in initiating drug therapy,
and monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects);
f. describe the pathophysiology of selected disease states and explain the rationale for
drug therapy;
g. summarise the therapeutic approach to management of these diseases including
reference to the latest available evidence;
h. discuss the controversies in drug therapy;
i. discuss the preparation of individualised therapeutic plans based on diagnosis; and
j. identify the patient-specific parameters relevant in initiating drug therapy, and
monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects).
This document discusses several respiratory diseases including pulmonary emphysema, chronic obstructive pulmonary disease, atelectasis, pneumonia, tuberculosis, asthma, and respiratory failure. Pulmonary emphysema involves damage to the alveoli walls of the lungs due to smoking or air pollution, reducing lung function. Pneumonia is a lung infection that causes inflammation of the alveoli. Tuberculosis is a bacterial infection that primarily affects the lungs. Asthma involves constriction of the bronchioles causing difficulty breathing. Respiratory failure occurs when the lungs can no longer effectively oxygenate the blood or remove carbon dioxide.
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a preventable and treatable disease characterized by airflow limitation caused by cigarette smoking and exposure to other noxious particles. The document outlines the risk factors, pathogenesis, pathophysiology, symptoms, diagnosis, classification, and management of COPD. Spirometry is a key test for COPD diagnosis and assessment. The goals of treatment are to prevent progression, relieve symptoms, improve exercise tolerance, and prevent exacerbations.
Pneumonia is an infection that causes inflammation in the lungs. There are two main types: lobar pneumonia, which affects one lung lobe, and bronchopneumonia, which causes patches throughout both lungs. Pneumonia is usually caused by bacteria or viruses and risks factors include age, smoking, and pre-existing medical conditions. Symptoms may include fever, cough, and difficulty breathing. Diagnosis involves chest x-rays and cultures. Treatment focuses on antibiotics and symptom relief. Complications can include lung abscesses or fluid in the chest cavity.
1. Pneumonia is an inflammation of the lung parenchyma that presents with recent radiological shadowing. It can be misdiagnosed, mistreated, and under estimated.
2. Pneumonia is classified by aetiology (community acquired, hospital acquired, aspiration) and anatomy (lobar, bronchopneumonia).
3. Risk factors include age, comorbidities, respiratory conditions, lifestyle factors, and immunosuppressant therapy.
The document discusses lung abscess and bronchiectasis. It defines lung abscess as a suppurative lesion caused by infected lung tissue necrosis that forms cavities containing pus or fluid. Bronchiectasis is an abnormal, permanent dilation of the bronchi often caused by infection. The document outlines the epidemiology, pathogenesis, clinical features, investigations, management, and prevention of lung abscess and bronchiectasis. It describes the most common causes and pathogens, as well as signs and symptoms, management with antibiotics and drainage, and importance of preventing aspiration to control the conditions.
Chronic Obstructive Pulmonary Disease (COPD) is an irreversible lung disease characterized by limited airflow and an abnormal inflammatory response in the lungs caused by long-term exposure to harmful particles like cigarette smoke. The main symptoms are breathlessness, cough, and wheezing. Diagnosis is based on a history of symptoms and cigarette smoking, and confirmed with lung function tests showing reduced airflow. Treatment focuses on smoking cessation and drug therapy with bronchodilators and corticosteroids to manage symptoms and reduce exacerbations.
Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases including chronic bronchitis and emphysema that are characterized by persistent airflow limitation. The main causes of COPD are tobacco smoking, exposure to secondhand smoke, and air pollution. Symptoms include cough, sputum production, and shortness of breath. Diagnosis involves assessing symptoms, lung function tests, and chest imaging. Treatment focuses on smoking cessation, medications to relieve symptoms and prevent exacerbations, pulmonary rehabilitation, and managing complications.
This document summarizes several respiratory system diseases including chronic obstructive pulmonary disease (COPD) and chronic restrictive pulmonary disease. It describes the four entities that comprise COPD - bronchial asthma, chronic bronchitis, emphysema, and bronchiectasis. For each condition, it outlines characteristics, pathologic findings, and types. It also discusses several occupational lung diseases that fall under chronic restrictive pulmonary disease, including coal workers' pneumoconiosis, silicosis, and asbestosis.
Pneumonia is an inflammation of the lung parenchyma caused by various microorganisms, including bacteria, mycobacteria, fungi, and viruses.
Pneumonitis is a more general term that describes the inflammatory process in the lung tissue that may predispose and Pneumonia is an inflammation of the lung parenchyma that is caused by a microbial agent.
place the patient at risk for microbial invasion.
Pneumonia is classified into four: community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), pneumonia in the immunocompromised host, and aspiration pneumonia.
This document discusses chronic kidney disease and its management. It defines chronic kidney disease as kidney damage and decreased kidney function for over 3 months. It then discusses the pathophysiology of chronic renal failure, noting the loss of nephrons and failure of kidney roles in fluid balance, waste excretion, and hormone regulation. Common causes of chronic kidney disease are listed, and the progression from initial insult to end stage renal disease is described. Diagnosis involves history, exam, and blood and urine tests to assess kidney function and check for underlying etiologies. Treatment focuses on slowing progression, managing complications, and preparing for renal replacement therapies like dialysis and transplantation.
DENTAL MANAGEMENT OF PATIENTS WITH REPIRATORY DISEASES 2809-1.pptxSamuelAgboola11
This document discusses the relationship between the respiratory and oral systems. It begins by describing the structures and functions of the respiratory system, including the conducting airways, lungs, muscles of respiration, and control centers in the central nervous system. It then discusses several respiratory diseases like viral upper respiratory infections, asthma, pneumonia, and tuberculosis. For each disease, it covers signs and symptoms, pathogenesis, and dental management considerations. The document emphasizes the importance of oral health in preventing respiratory infections and managing patients with respiratory diseases.
The document discusses various lower respiratory disorders including:
1. Atelectasis, which is the collapse or closure of the lung resulting in reduced gas exchange. Pneumonia, an inflammation of the lung parenchyma caused by a microbial agent, is discussed along with types such as bacterial, viral, fungal and aspiration pneumonia.
2. Pulmonary tuberculosis, an infectious lung disease caused by the bacterium Mycobacterium tuberculosis, is usually spread through the air. Lung abscess, defined as necrosis of lung tissue and cavity formation caused by microbial infection, is also covered.
3. Other conditions mentioned include pleural conditions, pulmonary edema, acute respiratory failure, pulmonary embolism
The document summarizes key aspects of respiratory pathology. It discusses the anatomy and function of the lungs, as well as various lung diseases including congenital anomalies, atelectasis, pulmonary edema, acute lung injury, obstructive and restrictive lung diseases, infectious diseases like pneumonia and tuberculosis, and cancers. Diseases are described in terms of their definition, causes, pathogenesis, clinical presentation, complications and morphological features.
This document provides an overview of pulmonary edema through defining it, discussing anatomy and physiology, epidemiology, classification, pathogenesis, staging, causes, clinical manifestations, diagnosis, medical management, nursing diagnosis, interventions, complications, and expected outcomes. It summarizes the key points of pulmonary edema for medical professionals.
This document discusses respiratory failure, including its definition, types, causes, clinical manifestations, diagnostic evaluations, management, and complications. Respiratory failure is when the respiratory system fails to adequately oxygenate the blood or eliminate carbon dioxide. It can be classified as hypoxemic or hypercapnic. Acute respiratory failure develops rapidly over hours while chronic develops over days. Management involves treating the underlying cause, providing oxygen supplementation, monitoring vital signs, and supporting respiratory function. Complications can affect the lungs, heart, gastrointestinal system, and risk of infection.
it involves the general principles of poisoning treatment and various basic principles of management of poisoning IT IS USEFULL FOR THE IV.PHARM D STUDENTS AND MEDICAL STUDENTS
Respiratory dis. presentation1 for gen path copy (2)Art Arts
1) Respiratory diseases are mainly caused by inhalation of infectious agents, allergens, irritants, and carcinogens. The lungs are open to the environment and lack regenerative abilities.
2) Chronic obstructive pulmonary diseases (COPD) include chronic bronchitis, emphysema, bronchiectasis, and asthma. Tobacco smoke is a major cause and leads to airway obstruction.
3) Pneumonia can result from impaired pulmonary defenses and host resistance. Bacterial and viral pathogens are common causes and treatment involves antibiotics and supportive care.
The document provides information on pulmonary emergencies including pneumonia, asthma, and chronic obstructive pulmonary disease (COPD). It discusses the common causes, clinical features, diagnostic tests, treatment, and management of each condition. For pneumonia, it outlines the typical bacterial and atypical agents that cause pneumonia in different age groups. It also lists antibiotics commonly used to treat pneumonia. For asthma, it describes the pathophysiology and emphasizes the importance of optimizing lung function and oxygenation. For COPD, it defines the components of the disease and notes the role of medications like bronchodilators, corticosteroids, and antibiotics in management.
Etiopathogenesis and pharmacotherapy of DIPDs
a. the pathophysiology of selected disease states and the rationale for drug therapy;
b. the therapeutic approach to management of these diseases;
c. the controversies in drug therapy;
d. the importance of preparation of individualised therapeutic plans based on diagnosis;
e. needs to identify the patient-specific parameters relevant in initiating drug therapy,
and monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects);
f. describe the pathophysiology of selected disease states and explain the rationale for
drug therapy;
g. summarise the therapeutic approach to management of these diseases including
reference to the latest available evidence;
h. discuss the controversies in drug therapy;
i. discuss the preparation of individualised therapeutic plans based on diagnosis; and
j. identify the patient-specific parameters relevant in initiating drug therapy, and
monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects).
This document discusses several respiratory diseases including pulmonary emphysema, chronic obstructive pulmonary disease, atelectasis, pneumonia, tuberculosis, asthma, and respiratory failure. Pulmonary emphysema involves damage to the alveoli walls of the lungs due to smoking or air pollution, reducing lung function. Pneumonia is a lung infection that causes inflammation of the alveoli. Tuberculosis is a bacterial infection that primarily affects the lungs. Asthma involves constriction of the bronchioles causing difficulty breathing. Respiratory failure occurs when the lungs can no longer effectively oxygenate the blood or remove carbon dioxide.
Similar to vishu-druginducedpulmonarydiseases-1-170913181832.pptx (20)
lakshya.pptx complete information regardingPavani555
The document proposes an alert system that identifies threat zones and provides real-time alerts in oil and gas refineries. It measures parameters like wind direction and speed to calculate the radius of gas spread after an explosion. The system categorizes alerts into red, orange and yellow zones based on severity and activates alarms prioritizing areas near the gas dispersion direction. This helps people be aware of gas leaks and rescue themselves.
chemotherapy induced nausea and vomiting-200328181619.pptxPavani555
This document discusses chemotherapy induced nausea and vomiting (CINV). It defines the different types of CINV including acute, delayed, anticipated, breakthrough and refractory. It lists risk factors and the emetic risk of different chemotherapy agents. It describes the pathogenesis, clinical presentation, complications, diagnosis and non-pharmacological treatments of CINV. It provides details of pharmacological treatments for different levels of emetic risk, including the use of NK1 receptor antagonists, 5-HT3 receptor antagonists, benzodiazepines and corticosteroids. It also lists common adverse effects of drugs used to treat CINV.
Tuberculosis is an infectious disease caused primarily by Mycobacterium tuberculosis that usually affects the lungs. It spreads through inhaling droplets from an infected person when they cough, sneeze, or spit. In 2021, an estimated 10.6 million people fell ill with TB worldwide, including 6 million men and 3.4 million women. TB is classified into two main types and can affect other parts of the body beyond the lungs. Diagnosis involves bacteriological tests, sputum cultures, chest x-rays, and tuberculin skin tests. Risk factors include sex, ethnicity, age, genetics, and family history.
eczema complete information including treatmentPavani555
This document discusses eczema, including its definition, epidemiology, types, risk factors, clinical presentation, complications, diagnosis, treatment, and drugs used. It defines eczema as itchy erythematous eruptions consisting of ill-defined erythematous plaques or papules. It affects 15-20% of children and 1-3% of adults worldwide. Types include atopic, allergic contact dermatitis, irritant contact dermatitis, discoid, statis, and asteatotic eczema. Risk factors include allergens, irritants, age, occupation, and comorbid conditions. Treatment involves avoidance of risk factors, emollients, phototherapy
impetigo- complete information including treatmentPavani555
Impetigo is a common bacterial skin infection that affects the superficial layers of the epidermis. It is highly contagious and most often caused by Staphylococcus aureus or Streptococcus pyogenes bacteria. Impetigo commonly affects children in developing countries and the incidence in India is approximately 6%. It presents as vesicles or pustules that rupture and form honey-colored crusts. Treatment involves topical or oral antibiotics like mupirocin, retapamulin, cephalexin, or amoxicillin-clavulanic acid. Proper hygiene and wound care are also important to prevent the spread of impetigo.
psoriasis complete information including therapyPavani555
This document discusses psoriasis, a chronic skin condition characterized by rapid skin cell production. Key points include: psoriasis causes patches of thickened, inflamed skin with silvery scales; it is caused by genetic and environmental factors and may be triggered by stress or injury; common treatment approaches are topical creams/ointments, light therapy, and systemic drugs like methotrexate. The goal of treatment is to slow skin cell turnover and resolve lesions.
This document discusses different methods for pharmacovigilance including spontaneous reporting, active surveillance, sentinel sites, cohort event monitoring, and registries. Spontaneous reporting involves voluntary reporting of adverse drug reactions by healthcare professionals and can provide early signals of unrecognized toxicity. Active surveillance methods like cohort event monitoring and sentinel sites pursue to determine a specific number of adverse events through continuous organized monitoring.
Roles and responsibilities of investigatorPavani555
This document defines key roles in clinical trials including sponsors, investigators, clinical research associates (CRAs), auditors, contract research coordinators, and regulatory authorities. Sponsors are responsible for initiating, managing, and financing trials. Investigators conduct trials and ensure participant safety and protocol compliance. CRAs monitor trials to ensure data quality and safety reporting. Auditors ensure compliance with regulations. Coordinators record trial data. Regulatory authorities review trials and ensure drug safety.
Impetigo is a common skin infection caused by Staphylococcus aureus or Streptococcus pyogenes bacteria. It presents as fluid-filled blisters or pustules that rupture and form golden crusts. It is highly contagious through direct contact. Treatment involves topical or oral antibiotics like mupirocin ointment, dicloxacillin, or cephalexin for 7-10 days. Proper hygiene and avoiding spread is important for prevention.
A Case presentation on right upper lobe pneumonia and b/l renal calculiPavani555
- The patient presented with fever, cough with yellow expectoration, and shortness of breath for 10 days. Chest X-ray revealed right upper lobe pneumonia.
- Physical exam and lab results also indicated bilateral renal calculi, with symptoms of flank pain and decreased urine output.
- The patient was diagnosed with right upper lobe pneumonia and bilateral renal calculi. Treatment included antibiotics, diuretics, and medications to control blood pressure and normalize kidney function.
Basics of Electrocardiogram
CONTENTS
●Conduction System of the Heart
●What is ECG or EKG?
●ECG Leads
●Normal waves of ECG.
●Dimensions of ECG.
● Abnormalities of ECG
CONDUCTION SYSTEM OF THE HEART
ECG:
●ECG is a graphic record of the electrical activity of the heart.
●Electrical activity precedes the mechanical activity of the heart.
●Electrical activity has two phases:
Depolarization- contraction of muscle
Repolarization- relaxation of muscle
ECG Leads:
●6 Chest leads
●6 Limb leads
1. Bipolar Limb Leads:
Lead 1- Between right arm(-ve) and left arm(+ve)
Lead 2- Between right arm(-ve) and left leg(+ve)
Lead 3- Between left arm(-ve)
and left leg(+ve)
2. Augmented unipolar Limb Leads:
AvR- Right arm
AvL- Left arm
AvF- Left leg
3.Chest Leads:
V1 : Over 4th intercostal
space near right sternal margin
V2: Over 4th intercostal space near left sternal margin
V3:In between V2 and V4
V4:Over left 5th intercostal space on the mid
clavicular line
V5:Over left 5th intercostal space on the anterior
axillary line
V6:Over left 5th intercostal space on the mid
axillary line.
Normal ECG:
Waves of ECG:
P Wave
•P Wave is a positive wave and the first wave in ECG.
•It is also called as atrial complex.
Cause: Atrial depolarisation
Duration: 0.1 sec
QRS Complex:
•QRS’ complex is also called the initial ventricular complex.
•‘Q’ wave is a small negative wave. It is continued as the tall ‘R’ wave, which is a positive wave.
‘R’ wave is followed by a small negative wave, the ‘S’ wave.
Cause:Ventricular depolarization and atrial repolarization
Duration: 0.08- 0.10 sec
T Wave:
•‘T’ wave is the final ventricular complex and is a positive wave.
Cause:Ventricular repolarization Duration: 0.2 sec
Intervals and Segments of ECG:
P-R Interval:
•‘P-R’ interval is the interval
between the onset of ‘P’wave and onset of ‘Q’ wave.
•‘P-R’ interval cause atrial depolarization and conduction of impulses through AV node.
Duration:0.18 (0.12 to 0.2) sec
Q-T Interval:
•‘Q-T’ interval is the interval between the onset of ‘Q’
wave and the end of ‘T’ wave.
•‘Q-T’ interval indicates the ventricular depolarization
and ventricular repolarization,
i.e. it signifies the
electrical activity in ventricles.
Duration:0.4-0.42sec
S-T Segment:
•‘S-T’ segment is the time interval between the end of ‘S’ wave and the onset of ‘T’ wave.
Duration: 0.08 sec
R-R Interval:
•‘R-R’ interval is the time interval between two consecutive ‘R’ waves.
•It signifies the duration of one cardiac cycle.
Duration: 0.8 sec
Dimension of ECG:
How to find heart rhytm of the heart?
Regular rhytm:
Irregular rhytm:
More than or less than 4
How to find heart rate using ECG?
If heart Rhytm is Regular :
Heart rate =
300/No.of large b/w 2 QRS complex
= 300/4
=75 beats/mins
How to find heart rate using ECG?
If heart Rhytm is irregular:
Heart rate = 10×No.of QRS complex in 6 sec 5large box = 1sec
5×6=30
10×7 = 70 Beats/min
Abnormalities of ECG:
Cardiac Arrythmias:
1.Tachycardia
Heart Rate more than 100 beats/min
The Importance of Black Women Understanding the Chemicals in Their Personal C...bkling
Certain chemicals, such as phthalates and parabens, can disrupt the body's hormones and have significant effects on health. According to data, hormone-related health issues such as uterine fibroids, infertility, early puberty and more aggressive forms of breast and endometrial cancers disproportionately affect Black women. Our guest speaker, Jasmine A. McDonald, PhD, an Assistant Professor in the Department of Epidemiology at Columbia University in New York City, discusses the scientific reasons why Black women should pay attention to specific chemicals in their personal care products, like hair care, and ways to minimize their exposure.
Test bank clinical nursing skills a concept based approach 4e pearson educati...rightmanforbloodline
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Emotional and Behavioural Problems in Children - Counselling and Family Thera...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
As Mumbai's premier kidney transplant and donation center, L H Hiranandani Hospital Powai is not just a medical facility; it's a beacon of hope where cutting-edge science meets compassionate care, transforming lives and redefining the standards of kidney health in India.
Sectional dentures for microstomia patients.pptxSatvikaPrasad
Microstomia, characterized by an abnormally small oral aperture, presents significant challenges in prosthodontic treatment, including limited access for examination, difficulties in impression making, and challenges with prosthesis insertion and removal. To manage these issues, customized impression techniques using sectional trays and elastomeric materials are employed. Prostheses may be designed in segments or with flexible materials to facilitate handling. Minimally invasive procedures and the use of digital technologies can enhance patient comfort. Education and training for patients on prosthesis care and maintenance are crucial for compliance. Regular follow-up and a multidisciplinary approach, involving collaboration with other specialists, ensure comprehensive care and improved quality of life for microstomia patients.
Test bank advanced health assessment and differential diagnosis essentials fo...rightmanforbloodline
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Simple Steps to Make Her Choose You Every DayLucas Smith
Simple Steps to Make Her Choose You Every Day" and unlock the secrets to building a strong, lasting relationship. This comprehensive guide takes you on a journey to self-improvement, enhancing your communication and emotional skills, ensuring that your partner chooses you without hesitation. Forget about complications and start applying easy, straightforward steps that make her see you as the ideal person she can't live without. Gain the key to her heart and enjoy a relationship filled with love and mutual respect. This isn't just a book; it's an investment in your happiness and the happiness of your partner
Ensure the highest quality care for your patients with Cardiac Registry Support's cancer registry services. We support accreditation efforts and quality improvement initiatives, allowing you to benchmark performance and demonstrate adherence to best practices. Confidence starts with data. Partner with Cardiac Registry Support. For more details visit https://cardiacregistrysupport.com/cancer-registry-services/
5. 1) BRONCHOSPASM
Most common drug induced pulmonary adverse event
Clinical presentation is the same as with non-drug
induced bronchospasm
Risk factors include pre-existing
hyper reactive lung disease,
smoking, advanced age
and respiratory infections
7. Narcotic analgesics, ethylene
diamine, Local anaesthetics,
benzalkonium chloride
Anaphylactoid reaction
ACE inhibitor, Hydrocortisone,
piperazine, isoproterenol,
Losartan, Mono sodium glutamate
Unknown mechanism
MANAGEMENT
• Withdrawal and avoidance of causative agents
• Treat acute anaphylaxis with low doses of injectable
epinephrine
• Oxygen, corticosteroids, antihistamines
• Inhaled β2-agonists are useful for persistent
bronchospasm
8. ASPIRIN INDUCED BRONCHOSPASM
It begins within minutes to hours following ingestion of
aspirin
Clinical presentation includes rhinorrhea, flushing of
head and neck, conjuctivitis
MOA is inhibition of cycloxygenase
Definitive diagnosis is done by oral provocation test
Treatment includes desensitization
or avoidance
10. PULMONARY EDEMA
• Cardiogenic and non cardiogenic
• Symptoms include dyspnea, chest discomfort, tachypnea,
hypoxemia, foamy tracheal exudates
• Management focuses on adequate life support and limit
the accumulation of extravascular water in the lungs.
a) CARDIOGENIC
• It have an insidious onset
• Symptoms are vague fatigue, mild pedal edema ,
exertional dyspnea
11. • Iatrogenic cause includes IV fluids with resultant
cardiovascular fluid overload
• Eg: IV fluids, contrast media, magnesium sulfate
b) NON- CARDIOGENIC
• It occurs via drug related increase in capillary pulmonary
permeability
• Eg: Antineoplastic agents, IV β2-agonist, cocaine,
hydrocholorothiazide, naloxone, opiates, salicylates
12. 3) PULMONARY HYPERTENSION
• It is rare, but life threatening
• Symptoms include exertional dyspnea, fatigue,
weakness, chest pain, syncope
DRUGS CAUSING PULMONARY HYPERTENSION
Appetite supressants
fenfluramine derivatives
Amphetamine derivatives
Serotonin specific reuptake inhibitors
14. 4) INTERSTITIAL LUNG DISEASE (ILD)
• It can lead to respiratory failure
• Symptoms include non productive cough, dyspnea, low
grade fever
• Oxidant injury either through increased production of
oxidants or inhibition of antioxidant accounts for
majority of ILD
15.
16. 4a) INTERSTITIAL INFILTRATES / PNEUMONIA
Diseases involving the space between the alveolus and
capillary.
The infiltrates consists of fluid and or cells that gather in
the areas of the lungs
Drugs causing interstitial pneumonia:
• Epidermal growth factor receptor antagonist
• Tyrosine kinase inhibitors
• Methotrexate
• Nitrofurantoin
17. 4b) PULMONARY FIBROSIS
• It is characterized by accumulation of excessive
connective tissue in the lungs
• Activation of coagulation cascade and generation of
coagulation proteases play a key role.
Drugs that causes pulmonary fibrosis:
Cytotoxic drugs like bleomycin, busulfan, carmustine,
cyclophosphamide, mitomycin
Non cytotoxic drugs like amiodarone, bromocryptine,
ergot derivatives, heroin, methysergide
18.
19. 4C) BRONCHIOLITIS OBLITERANS ORGANIZING
PNEUMONIA
• It is an inflammation of the lungs characterized by
alveolar fibrosis
• Symptoms include dyspnea, low-grade fever, acute
pleuritic chest pain
• More than 20 medications are associated with BOOP
Drugs causing BOOP
• Antimicrobials, Amphotericin B, Cephalosporin,
Minocycline, Nitrofurantoin drugs, Cytotoxic drugs
21. 5) PULMONARY EOSINOPHILIA
• It is characterized by pulmonary infiltration of
eosinophils in alveolar spaces, the interstitium or
both
• Pulmonary infiltrates with eosinophilia (PIE)
• Diagnosis is done by lung biopsy
• Loeffler syndrome
• Churg – Strauss syndrome (CSS)
24. 6) PLEURAL INFLAMMATION
• It range in presentation from asymptomatic effusion to
acute pleuritis to symptomatic pleural thickening
• Symptoms are pleuritic chest pain, dyspnea, and cough
• Mechanism include hypersensitivity or allergic reaction,
direct toxicity, increased production of oxygen-free
radicals, suppression of antioxidant defenses, and
chemically-induced inflammation
26. 7) DIFFUSE ALVEOLAR HEMORRHAGE (DAH)
AND VASCULITIS
• DAH is characterized by bleeding from pulmonary
capillaries, leading to the accumulation of red blood cells in
the alveolar spaces
• Symptoms include varying degrees of hemoptysis, cough,
and progressive dyspnea
• Drug-related pathogenic mechanisms include
hypersensitivity reaction, direct toxicity diffuse alveolar
damage (DAD), and coagulation defects
28. 8) DIFFUSE ALVEOLAR DAMAGE (DAD)
• In DAD, the alveolar epithelial cells are sloughed, and
the lung interstitium becomes edematous.
• Chronic inflammation and fibroproliferation of the
alveolar walls can present early in the process
• DAD presents with dyspnea, diffuse pulmonary
infiltrates
30. 9) DRUG HYPERSENSITIVITY SYNDROME
(DHS)
• DHS is a systemic idiosyncratic reaction
• It is defined by the presence of fever, rash, and organ
involvement, including pneumonitis
• Clinical presentations may involve dermatologic,
hematologic, lymphatic, or internal organ systems.
• Management involves drug withdrawal, supportive care
and corticosteroid therapy
32. 10) AMIODARONE INDUCED PULMONARY
TOXICITY (APT)
• APT has an average onset of 18-24 months
• It can present as various patterns of pulmonary toxicity
• Symptoms include fatigue, dyspnea, nonproductive
cough, pleuritic chest pain, crackles , weight loss
• MOA : During chronic therapy amiodarone and its
metabolic product DEAm accumulate in lungs which are
toxic to the lung cells
34. REFERENCES
1) Koda-Kimble M A, Young L Y, Williams B R, Corelli R
L, et al. Applied Therapeutics- The Clinical Use of Drugs.
In: Kubota D S, Chan J editor. Drug induced pulmonary
disorders.9th edition:25.1-25.13
2) Dipiro J T, Talbert R L, Yee G C, Matzke G R, et
al.Pharmacotherapy- A Pathophysiological Approach. In:
Raissy H H, Harkins M,editor.Drug induced pulmonary
diseases New York: Mc Graw Hill Professional.9th edition